Cubist Systematic Strategies, LLC Bio Atla, Inc. Transaction History

Cubist Systematic Strategies, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$2.83 - $3.87 $1,548 - $2,116	547 Added 1.25%	44,476 $133,000
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $39,824 - $142,848	17,315 Added 65.06%	43,929 $117,000
Q4 2022 Feb 14, 2023	BUY	$7.63 - $11.01 $75,277 - $108,624	9,866 Added 58.91%	26,614 $219,000
Q3 2022 Nov 14, 2022	SELL	$2.94 - $11.87 $45,290 - $182,857	-15,405 Reduced 47.91%	16,748 $129,000
Q2 2022 Aug 15, 2022	SELL	$2.13 - $5.38 $83,300 - $210,401	-39,108 Reduced 54.88%	32,153 $92,000

Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $78,572 - $336,894	17,939 Added 33.64%	71,261 $356,000
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $409,393 - $666,879	21,547 Added 67.81%	53,322 $1.05 Million
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $935,456 - $1.39 Million	31,775 New	31,775 $935,000

24.8M

140K

4.6K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $47.9M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.